

the proteins as well as nucleic acid constructs of SWP-1 and SWP-2. A third series of claims covers the administration and use of SWP-1 and SWP-2, either as whole proteins, immunogenic fragments or nucleic acid expression constructs along with a pharmaceutically acceptable carrier for the treatment of microsporidiosis. A final set of claims include the administration of certain ligands to SWP-2 in pharmaceutically acceptable carriers for the prevention and treatment of microsporidiosis.

Dated: March 2, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-5224 Filed 3-8-04; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institutes of Health Announcement of Scientific Conference

**ACTION:** Notice.

**UPCOMING CONFERENCE:** Carnitine: The Science Behind a Conditionally Essential Nutrient

**SUMMARY:** The National Institute of Child Health and Human Development, the National Center for Complementary and Alternative Medicine, the National Institute of Mental Health, and the Office of Dietary Supplements are sponsoring a conference, *Carnitine: The Science Behind a Conditionally Essential Nutrient*. The conference will take place on March 25 and 26, 2004 at the Natcher Conference Center on the campus of the National Institutes of Health in Bethesda, Maryland.

This conference will address the following topics related to Carnitine:

- Basic physiology and pharmacology;
- Carnitine replacement in primary and secondary carnitine deficiency syndromes; and
- Carnitine supplementation in exercise, cardiovascular disease, obesity, diabetes, HIV infection, aging, cancer, and infertility.

The overall conference goals are to:

- Provide the scientific and lay communities with the most updated, evidence-based information regarding the role of carnitine in health and disease prevention;
- Clarify issues relevant to appropriate uses of carnitine; and

- Propose new areas of research for future studies in this nutrient.

**ACCREDITATIONS:** The American College of Nutrition is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

The American College of Nutrition designates this continuing medical education activity for 12.5 CME credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

The Certification Board for Nutrition Specialist (CBNS) authorizes 12.5 CNE credits hours for Certified Nutrition Specialists (CNS).

**FOR FURTHER INFORMATION CONTACT:** The conference Web site at [www.scgcorp.com/carnitine2004/index.htm](http://www.scgcorp.com/carnitine2004/index.htm).

Dated: March 4, 2004.

**Christy Thomsen,**

*Director, Office of Communications and Public Liaison, National Center for Complementary and Alternative Medicine, National Institutes of Health.*

[FR Doc. 04-5297 Filed 3-8-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Consensus Development Conference on Celiac Disease; Notice

Notice is hereby given of the National Institutes of Health (NIH) Consensus Development Conference on "Celiac Disease" to be held June 28-30, 2004, in the NIH Natcher Conference Center, 45 Center Drive, Bethesda, Maryland 20892. The conference will begin at 8:30 a.m. on June 28 and 29, and at 9 a.m. on June 30, and will be open to the public.

Celiac disease is a disorder primarily affecting the gastrointestinal tract that is characterized by chronic inflammation of the mucosa, which leads to atrophy of intestinal villi, malabsorption, and protean clinical manifestations which may begin either in childhood or adult life. Symptoms can include abdominal cramping, bloating, and distention, and untreated celiac disease may lead to vitamin and mineral deficiencies, osteoporosis and other problems.

At the present time, celiac disease is widely considered to be a rare disease in the United States. However, recent studies, primarily in Europe but also in the United States, suggest that its prevalence is much higher than previous estimates, raising the concern

that the disease is widely under-recognized. Recent progress in identification of autoantigens in celiac disease have led to the development of new serological diagnostic tests, but the appropriate use of testing strategies has not been well defined. Some patients with celiac disease may be at risk for non-Hodgkin's lymphoma, a rare cancer affecting the gastrointestinal tract. It is not yet clear, however, what the impact of this observation should be on diagnostic and treatment strategies.

This two-and-a-half-day conference will examine the current state of knowledge regarding celiac disease and identify directions for future research.

During the first day-and-a-half of the conference, experts will present the latest research findings on celiac disease to an independent panel. After weighing all of the scientific evidence, the panel will draft a statement, addressing the following key questions:

- How is celiac disease diagnosed?
- How prevalent is celiac disease?
- What are the manifestations and long-term consequences of celiac disease?
- Who should be tested for celiac disease?
- What is the management of celiac disease?
- What are the recommendations for future research on celiac disease and related conditions?

On the final day of the conference, the panel chairperson will read the draft statement to the conference audience and invite comments and questions. A press conference will follow, to allow the panel and chairperson to respond to questions from the media.

The primary sponsors of this meeting are the National Institute of Diabetes and Digestive and Kidney Diseases and the NIH Office of Medical Applications of Research.

Advance information about the conference and conference registration materials may be obtained from American Institutes for Research of Silver Spring, Maryland, by calling 888-644-2667, or by sending e-mailing to [celiac@air.org](mailto:celiac@air.org). American Institutes for Research's mailing address is 10720 Columbia Pike, Silver Spring, MD, 20901. Registration information is also available on the NIH consensus Development Program Web site at <http://consensus.nih.gov>.

*Please Note:* The NIH has recently instituted new security measures to ensure the safety of NIH employees and property. All visitors must be prepared to show a photo ID upon request. Visitors may be required to pass through a metal detector and have bags, backpacks, or purses inspected or x-rayed as they enter NIH buildings. For

more information about the new security measures at NIH, please visit the Web site at <http://www.nih.gov/about/visitorssecurity.htm>.

Dated: March 2, 2004.

**Raynard S. Kington,**

*Deputy Director, National Institutes of Health.*

[FR Doc. 04-5221 Filed 3-8-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel Review of Mentored Patient-Oriented Research Car. Devel. (K23), Midcareer Investigator Award in Patient-Oriented Res. (K24), and Mentored Quantitative Res. Career Develop. (K25) Awards.

*Date:* June 3-4, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Nancy L. Di Fronzo, PhD, Scientific Review Administrator, Review Branch, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, NIH, 6701 Rockledge II, Room 7196 (MSC 7924), Bethesda, MD 20892, (301) 435-0288.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: March 2, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-5220 Filed 3-8-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Initial Review Group Reproduction, Andrology, and Gynecology Subcommittee.

*Date:* April 1-2, 2004.

*Time:* 7 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* American Inn of Bethesda, 8130 Wisconsin Ave., Bethesda, MD 20814.

*Contact Person:* Jon M. Ranhand, PhD, Scientist Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892, [ranhandj@mail.nih.gov](mailto:ranhandj@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: March 2, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-5219 Filed 3-8-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Immunoconjugate for the Treatment of Mesothelin-Expressing Cancers

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the Food and Drug Administration and the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in: E-002-1996/0: Nucleic Acid Encoding Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers (issued as U.S. patent 6,153,430); E-002-1996/1: Mesothelium Antigen and Methods and Kits for Targeting It (issued as U.S. patent 6,083,502); E-021-1998/0: Antibodies, Including Fv Molecules, and Immunoconjugates Having High Binding Affinity for Mesothelin and Methods for Their Use (filed as PCT/US98/25270 on November 25, 1998); and E-216-2000/1 (PCT application PCT/US01/18503, combining 60/211,331 and 60/213,804): Pegylation of Linkers Improves Antitumor Activity and Reduces Toxicity of Immunoconjugates, to Enzon Pharmaceuticals, Inc., which is located in Needham, MA. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to the use of the SS1P immunoconjugate for the treatment of mesothelin-expressing cancers.

**DATES:** Only written comments and/or license applications which are received by the National Institutes of Health on or before May 10, 2004, will be considered.

**ADDRESSES:** Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Brenda J. Hefti, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852-3804; Telephone: (301) 435-4632; Facsimile: (301) 402-0220; E-mail: [heftib@mail.nih.gov](mailto:heftib@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** This technology is an immunoconjugate, consisting of an anti-mesothelin antibody coupled to a killing moiety, specifically pseudomonas exotoxin (PE38). This immunotoxin is targeted towards mesothelin, and might be useful as a therapeutic for the treatment of mesothelin-expressing cancers such as mesotheliomas, ovarian cancers and pancreatic cancers.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The